BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

To Kill a Drug Company, Reorganize It


6/21/2012 8:27:58 AM

Can you fix a broken drug company research lab? Jack Scannell, the European pharmaceuticals analyst at Sanford C. Bernstein, recently held a conference on the future of drug research and development. On the last day, he had representatives from two of the most successful drug development organizations on the planet: Sean Bohen, who heads early resaerch and development at Genentech, part of Roche, which has had a legendary string of cancer drug successes; and Mads Krogsgaard Thomsen, the chief scientific officer at Novo Nordisk, one of the dominant players in diabetes and the best-performing big pharma stock over the past decade. This story is based on a transcript of their talks.

Read at Forbes

Forbes
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES